This inventor holds 3 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Riken Corporation. Active years: 2010-2012.
Company Filing History:
Years Active: 2010-2012
Title: Naoshi Dohmae: Innovator in Antibody and Glycoprotein Research
Introduction
Naoshi Dohmae is a prominent inventor based in Saitama, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies and mucin-type glycoproteins. With a total of 3 patents, his work has implications for medical research and therapeutic applications.
Latest Patents
Dohmae's latest patents include groundbreaking inventions such as antibodies that recognize cutting edges within the TGF-β activation controlling region. This invention aims to provide antibodies capable of detecting an active TGF-β generation reaction that is specific to pathogenesis, tissues, or isoforms. The antibodies are designed to specifically recognize respective cutting edges within protease cleavage sites in human TGF-β1, TGF-β2, and TGF-β3. Another notable patent involves a novel mucin-type glycoprotein and a method for its production. This mucin-type glycoprotein features a repeat structure with amino acid sequences that can be bound to sugar chains, offering potential applications in various biochemical fields.
Career Highlights
Naoshi Dohmae is associated with Riken Corporation, a leading research institution in Japan. His work at Riken has allowed him to explore innovative solutions in biotechnology and contribute to advancements in the understanding of protein interactions and functions.
Collaborations
Dohmae has collaborated with notable coworkers such as Wakako Kondo and Soichi Kojima. These collaborations have fostered a productive research environment, leading to significant advancements in their respective fields.
Conclusion
Naoshi Dohmae's contributions to antibody and glycoprotein research highlight his role as an influential inventor in biotechnology. His innovative patents and collaborations continue to pave the way for future advancements in medical and biochemical applications.